FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3112745025> ?p ?o ?g. }

• W3112745025 endingPage "394" @default.
• W3112745025 startingPage "388" @default.
• W3112745025 abstract "The ERK1/2 (RAS, RAF, MEK, ERK) and PI3K (PI3K, AKT, mTOR, PTEN) pathways are the chief signaling pathways for cellular proliferation, survival, and differentiation. Overactivation and hyperphosphorylation of the ERK1/2 & PI3K pathways is frequently observed in cancer and is associated with poor patient prognosis. While it is well known that genetic alterations lead to the dysregulation of the ERK1/2 & PI3K pathways, increasing evidence showcase that epigenetic alterations also play a major role in the regulation of the ERK1/2 & PI3K pathways. Protein Arginine Methyltransferase 5 (PRMT5) is a posttranslational modifier for multiple cellular processes, which is currently being tested as a therapeutic target for cancer. PRMT5 has been shown to be overexpressed in many types of cancers, as well as negatively correlated with patient survival. Numerous studies are indicating that as a posttranslational modifier, PRMT5 is extensively involved in regulating the ERK1/2 & PI3K pathways. In addition, a large number of in vitro and in vivo studies are demonstrating that PRMT5 inhibition, as well as PRMT5 and ERK1/2 & PI3K combination therapies, show significant therapeutic effects in many cancer types. In this review, we explore the vast interactions that PRMT5 has with the ERK1/2 & PI3K pathways, and we make the case for further testing of PRMT5 inhibition, as well as PRMT5 and ERK1/2 & PI3K combination therapies, for the treatment of cancer." @default.
• W3112745025 created "2020-12-21" @default.
• W3112745025 creator A5008413810 @default.
• W3112745025 creator A5029455802 @default.
• W3112745025 creator A5061548956 @default.
• W3112745025 creator A5062991182 @default.
• W3112745025 creator A5069675476 @default.
• W3112745025 date "2021-03-01" @default.
• W3112745025 modified "2023-10-17" @default.
• W3112745025 title "Protein Arginine Methyltransferase 5 (PRMT5) and the ERK1/2 & PI3K Pathways: A Case for PRMT5 Inhibition and Combination Therapies in Cancer" @default.
• W3112745025 cites W1596261235 @default.
• W3112745025 cites W1773455335 @default.
• W3112745025 cites W1927501023 @default.
• W3112745025 cites W1965766554 @default.
• W3112745025 cites W1967364632 @default.
• W3112745025 cites W1974024530 @default.
• W3112745025 cites W1976559908 @default.
• W3112745025 cites W1995242599 @default.
• W3112745025 cites W2009087843 @default.
• W3112745025 cites W2016740911 @default.
• W3112745025 cites W2025508342 @default.
• W3112745025 cites W2036400107 @default.
• W3112745025 cites W2039633811 @default.
• W3112745025 cites W2046857164 @default.
• W3112745025 cites W2052705131 @default.
• W3112745025 cites W2058310481 @default.
• W3112745025 cites W2062289724 @default.
• W3112745025 cites W2070634275 @default.
• W3112745025 cites W2071576183 @default.
• W3112745025 cites W2087884748 @default.
• W3112745025 cites W2091471291 @default.
• W3112745025 cites W2103245406 @default.
• W3112745025 cites W2105763574 @default.
• W3112745025 cites W2120687938 @default.
• W3112745025 cites W2130160735 @default.
• W3112745025 cites W2133528888 @default.
• W3112745025 cites W2157732830 @default.
• W3112745025 cites W2161810908 @default.
• W3112745025 cites W2162449964 @default.
• W3112745025 cites W2162861644 @default.
• W3112745025 cites W2165942284 @default.
• W3112745025 cites W2209279472 @default.
• W3112745025 cites W2223869627 @default.
• W3112745025 cites W2224519096 @default.
• W3112745025 cites W2240434829 @default.
• W3112745025 cites W2289373951 @default.
• W3112745025 cites W2429058495 @default.
• W3112745025 cites W2436425944 @default.
• W3112745025 cites W2489010315 @default.
• W3112745025 cites W2556291315 @default.
• W3112745025 cites W2576778623 @default.
• W3112745025 cites W2595713273 @default.
• W3112745025 cites W2615601352 @default.
• W3112745025 cites W2724296979 @default.
• W3112745025 cites W2732772919 @default.
• W3112745025 cites W2769020200 @default.
• W3112745025 cites W2775590543 @default.
• W3112745025 cites W2789281724 @default.
• W3112745025 cites W2793589490 @default.
• W3112745025 cites W2793801310 @default.
• W3112745025 cites W2794084157 @default.
• W3112745025 cites W2800832342 @default.
• W3112745025 cites W2804133093 @default.
• W3112745025 cites W2808913983 @default.
• W3112745025 cites W2864513547 @default.
• W3112745025 cites W2895446600 @default.
• W3112745025 cites W2895452350 @default.
• W3112745025 cites W2899349998 @default.
• W3112745025 cites W2901706397 @default.
• W3112745025 cites W2902294835 @default.
• W3112745025 cites W2908855808 @default.
• W3112745025 cites W2911032971 @default.
• W3112745025 cites W2915311655 @default.
• W3112745025 cites W2920068846 @default.
• W3112745025 cites W2921189699 @default.
• W3112745025 cites W2924910370 @default.
• W3112745025 cites W2930589698 @default.
• W3112745025 cites W2930598019 @default.
• W3112745025 cites W2936221900 @default.
• W3112745025 cites W2942506175 @default.
• W3112745025 cites W2944700391 @default.
• W3112745025 cites W2945851909 @default.
• W3112745025 cites W2948438687 @default.
• W3112745025 cites W2954917865 @default.
• W3112745025 cites W2964804212 @default.
• W3112745025 cites W2969086321 @default.
• W3112745025 cites W2970666008 @default.
• W3112745025 cites W2984097483 @default.
• W3112745025 cites W2986649907 @default.
• W3112745025 cites W2996606468 @default.
• W3112745025 cites W3016176606 @default.
• W3112745025 cites W3021252731 @default.
• W3112745025 cites W3025069247 @default.
• W3112745025 cites W3036172056 @default.
• W3112745025 cites W3036759197 @default.
• W3112745025 cites W3039031425 @default.
• W3112745025 cites W3045858142 @default.
• W3112745025 cites W39773280 @default.

• next